TCRX Insider Trading
Insider Ownership Percentage: 2.76%
Insider Buying (Last 12 Months): $86,659.98
Insider Selling (Last 12 Months): $951,885.08
TScan Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at TScan Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
TScan Therapeutics Share Price & Price History
Current Price: $1.38
Price Change: ▲ Price Increase of +0.03 (2.22%)
As of 03/31/2025 05:00 PM ET
TScan Therapeutics Insider Trading History
TScan Therapeutics Institutional Trading History
Data available starting January 2016
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More on TScan Therapeutics
Volume
862,980 shs
Average Volume
334,676 shs
Market Capitalization
$78.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.91
Who are the company insiders with the largest holdings of TScan Therapeutics?
Who are the major institutional investors of TScan Therapeutics?
Which major investors are selling TScan Therapeutics stock?
In the previous quarter, TCRX stock was sold by these institutional investors:
- Adage Capital Partners GP L.L.C.
- Marshall Wace LLP
- Jacobs Levy Equity Management Inc.
- Renaissance Technologies LLC
- Geode Capital Management LLC
Which major investors are buying TScan Therapeutics stock?
In the last quarter, TCRX stock was acquired by institutional investors including:
- abrdn plc
- Dimensional Fund Advisors LP
- Lynx1 Capital Management LP
- Tang Capital Management LLC
- Dauntless Investment Group LLC
- Bridgeway Capital Management LLC
- BNP Paribas Financial Markets
- Tocqueville Asset Management L.P.
Within the previous year, these company insiders have bought TScan Therapeutics stock:
- Lynx1 Capital Management Lp (Major Shareholder)
- Timothy J Barberich (Director)
- Barbara Klencke (Director)
Learn More investors buying TScan Therapeutics stock.